3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
5
Completed
3
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Pancreatic Neoplasms
4
Esophageal Neoplasms
2
Rectal Neoplasms
1
Phase I: To Determine the Maximum Tolerated Dose (MTD)
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Gastrointestinal Neoplasms
1
Gastric Adenocarcinoma
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
pembrolizumab
30
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
S 1 (combination)
×
Clear all
NCT00602745
2016-05-26
S-1 Pancreas
Sanofi
Phase 3
Terminated
61 enrolled